

Docket No. 2519-US-NP

2. Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-14 (*cancelled*)

15. (*Previously presented*) A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
- (i) a first isolated protein, comprising a polypeptide selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:2;
- (b) a polypeptide comprising amino acids 2-166 of SEQ ID NO:2;
- (c) a fragment of the polypeptide of SEQ ID NO:2; or
- (d) a polypeptide encoded by a nucleic acid sequence that is at least 95% identical to SEQ ID NO:1;

wherein said fragment of (i)(c) and said polypeptides of (i)(d) bind SEQ ID NO:4;

- (ii) a second isolated protein, comprising a polypeptide selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:4;
- (b) a polypeptide comprising amino acids 123-285 of SEQ ID NO:4; or
- (c) a polypeptide comprising amino acids 73-285 of SEQ ID NO:4;

- (iii) a test compound; and

- b. assaying for the level of interaction of the protein of (i) and the protein of (ii), wherein the affinity constant for protein (i) and protein (ii) is from 1.53×10^{-9} to 2.2×10^{-9} ;

such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

Docket No. 2519-US-NP

16. *(Previously presented)* The method of claim 15 wherein at least one of the proteins of (i) and the proteins of (ii) is labeled with a detectable moiety.
17. *(Previously presented)* The method of claim 15 wherein both the proteins of (i) and (ii) are soluble.
18. *(Previously presented)* The method of claim 17 wherein both the soluble protein of (i) and the soluble protein of (ii) are labeled with a detectable moiety.
19. *(Previously presented)* The method of claim 15 wherein the test compound is an antibody.
20. *(Previously presented)* The method of claim 19 wherein the antibody is a humanized antibody.
21. *(Previously presented)* The method of claim 15 wherein the composition is formed by adding the test compound to the protein of (i) and the protein of (ii).
22. *(Previously presented)* The method of claim 15 wherein step (b) comprises determining a dissociation constant of the interaction of the protein of (i) with the protein of (ii).
23. *(Previously presented)* The method of claim 15 wherein step (b) comprises assessing activation of the protein of (i) in a cell.
24. *(Previously presented)* The method of claim 23 wherein assessing activation of the protein of (i) in a cell is measured by calcium influx.
25. *(Previously presented)* The method of claim 15 wherein the protein of (ii) is a polypeptide comprising amino acids 123-285 of SEQ ID NO:4 or a polypeptide comprising amino acids 73-285 of SEQ ID NO:4.

Docket No. 2519-US-NP

26. *(Previously presented)* The method of claim 25 wherein the polypeptide comprising amino acids 123-285 of SEQ ID NO:4 or the polypeptide comprising amino acids 73-285 of SEQ ID NO:4 further comprises a leucine zipper domain.

27. *(Previously presented)* The method of claim 15 wherein the protein of (i) is a polypeptide comprising amino acids 2-166 of SEQ ID NO:2.

28. *(Previously presented)* The method of claim 27 wherein the polypeptide comprising amino acids 2-166 of SEQ ID NO:2 further comprises a Fc domain.

29. *(Previously presented)* A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
 - (i) an isolated protein selected from the group consisting of:
 - (a) the polypeptide of SEQ ID NO:2;
 - (b) a polypeptide comprising amino acids 2-166 of SEQ ID NO:2; and
 - (c) a fragment of the polypeptide of SEQ ID NO:2; wherein said fragment binds SEQ ID NO:4;
 - (ii) the polypeptide of SEQ ID NO:4; and
 - (iii) a test compound; and
- b. assaying for the level of interaction of the protein of (i) and the protein of (ii), wherein the affinity constant for protein (i) and protein (ii) is from 1.53×10^{-9} to 2.2×10^{-9} ;

such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

30. *(Previously presented)* A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
 - (i) the polypeptide of SEQ ID NO:2;
 - (ii) an isolated protein selected from the group consisting of:

Docket No. 2519-US-NP

- (a) the polypeptide of SEQ ID NO:4;
 - (b) a polypeptide comprising amino acids 123-285 of SEQ ID NO:4;
 - (c) a polypeptide comprising amino acids 73-285 of SEQ ID NO:4; and
 - (d) a fragment of the polypeptide of SEQ ID NO:4; wherein said fragment binds SEQ ID NO:2; and
- (iii) a test compound; and
- b. assaying for the level of interaction of the protein of (i) and the protein of (ii), wherein the affinity constant for protein (i) and protein (ii) is from 1.53×10^{-9} to 2.2×10^{-9} ;

such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

31. *(Cancelled)*

32. *(Previously presented)* A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
 - (i) the polypeptide of SEQ ID NO:2;
 - (ii) the polypeptide of SEQ ID NO:4; and
 - (iii) a test compound; and
- b. assaying for the level of interaction of the polypeptide of (i) and the polypeptide of (ii), wherein the affinity constant for protein (i) and protein (ii) is from 1.53×10^{-9} to 2.2×10^{-9} ;

such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

33. *(Cancelled)*

34. *(Cancelled)*

Docket No. 2519-US-NP

35. *(Previously presented)* The method of claim 25, wherein the polypeptide comprising amino acids 123-285 of SEQ ID NO:4 or the polypeptide comprising amino acids 73-285 of SEQ ID NO:4 further comprises a Fc domain.

36. *(Cancelled)*

37. *(Previously presented)* The method of claim 19, wherein the antibody is human.

38. *(Previously presented)* The method of claim 19, wherein the antibody comprises a Fab fragment.

39. *(Previously presented)* The method of claim 19, wherein the antibody comprises a F(ab')₂ fragment.

40. *(Previously presented)* A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
 - (i) a first isolated protein, comprising a polypeptide selected from the group consisting of:
 - (a) the polypeptide of SEQ ID NO:2; or
 - (b) a polypeptide comprising amino acids 2-166 of SEQ ID NO:2;
 - (ii) a second isolated protein, comprising a polypeptide selected from the group consisting of:
 - (a) the polypeptide of SEQ ID NO:4;
 - (b) a polypeptide comprising amino acids 123-285 of SEQ ID NO:4;
 - (c) a polypeptide comprising amino acids 73-285 of SEQ ID NO:4;
 - (d) a fragment of the polypeptide of SEQ ID NO:4; or
 - (e) a polypeptide encoded by a nucleic acid sequence that is at least 95% identical to SEQ ID NO:3;

Docket No. 2519-US-NP

wherein said fragment of (ii)(d) and said polypeptides of (ii)(e) bind
SEQ ID NO:2; and

(iii) a test compound; and

- b. assaying for the level of interaction of the protein of (i) and the protein
of (ii), wherein the affinity constant for protein (i) and protein (ii) is
from 1.53×10^{-9} to 2.2×10^{-9} ;

such that if the level obtained in step (b) differs from that obtained in the absence of
the test compound, a test compound that affects the interaction of the protein of (i)
and the protein of (ii) is identified.